Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the recipient of unusually large options trading on Wednesday. Traders acquired 11,595 put options on the stock. This represents an increase of approximately 1,703% compared to the typical volume of 643 put options.
Large investors have recently modified their holdings of the company. Oregon Public Employees Retirement Fund increased its stake in Endo International by 1.8% during the first quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock worth $621,000 after acquiring an additional 1,397 shares during the last quarter. Piedmont Investment Advisors Inc. increased its stake in Endo International by 3.5% during the fourth quarter. Piedmont Investment Advisors Inc. now owns 47,942 shares of the company’s stock worth $350,000 after acquiring an additional 1,607 shares during the last quarter. Mason Street Advisors LLC increased its stake in Endo International by 3.4% during the first quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock worth $515,000 after acquiring an additional 2,134 shares during the last quarter. Neuburgh Advisers LLC increased its stake in Endo International by 13.9% during the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock worth $181,000 after acquiring an additional 3,036 shares during the last quarter. Finally, Comerica Bank increased its stake in Endo International by 2.1% during the first quarter. Comerica Bank now owns 198,605 shares of the company’s stock worth $1,650,000 after acquiring an additional 4,001 shares during the last quarter. Institutional investors and hedge funds own 93.59% of the company’s stock.
ENDP traded down $0.23 during trading on Friday, reaching $4.95. 4,131,678 shares of the stock were exchanged, compared to its average volume of 3,353,259. Endo International has a 1 year low of $4.91 and a 1 year high of $18.50. The company has a market cap of $1.12 billion, a price-to-earnings ratio of 1.71 and a beta of 1.12.
Several research firms have commented on ENDP. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Endo International in a research report on Friday, March 1st. Zacks Investment Research lowered Endo International from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. ValuEngine raised Endo International from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Leerink Swann downgraded Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Finally, SunTrust Banks began coverage on Endo International in a research note on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price target on the stock. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have issued a buy rating to the company’s stock. Endo International presently has an average rating of “Hold” and a consensus target price of $14.88.
TRADEMARK VIOLATION WARNING: This report was posted by Rockland Register and is the sole property of of Rockland Register. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://rocklandregister.com/2019/05/31/investors-buy-large-volume-of-put-options-on-endo-international-endp.html.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
See Also: Cost of Capital Explained
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.